Clinuvel Pharmaceuticals Ltd

UR9A

Company Profile

  • Business description

    Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.

  • Contact

    535 Bourke Street
    Level 22
    MelbourneVIC3000
    AUS

    T: +61 396604900

    https://www.clinuvel.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    16

Stocks News & Analysis

stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks

Insignia Financial: Revised deal still attractive

The offer price is well above our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,982.1019.30-0.21%
CAC 407,850.43106.021.37%
DAX 4024,240.82198.920.83%
Dow JONES (US)45,010.29507.851.14%
FTSE 1009,061.4937.680.42%
HKSE25,668.02129.950.51%
NASDAQ21,020.02127.330.61%
Nikkei 22541,890.49719.171.75%
NZX 50 Index12,814.5920.530.16%
S&P 5006,358.9149.290.78%
S&P/ASX 2008,713.3023.90-0.27%
SSE Composite Index3,599.4417.140.48%

Market Movers